← Back to Search

Mesenchymal Stem Cell Therapy

BM-Allo.MSC for Coronavirus Disease

Phase 1
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 8, 15, 22, and 29
Awards & highlights

Study Summary

This is a phase 1b randomized, double-blind, placebo-controlled study in adult subjects with Coronavirus Disease 2019 (COVID-19). This clinical trial will evaluate the preliminary safety and efficacy of BM-Allo.MSC vs placebo in treating subjects with severe disease requiring ventilator support during COVID 19 infection.

Eligible Conditions
  • Coronavirus Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 8, 15, 22, and 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 8, 15, 22, and 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Death
Incidence of AEs
Mortality
+1 more
Secondary outcome measures
7-point ordinal scale
Hospitalization
Improvement of one category
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BM-Allo.MSCExperimental Treatment1 Intervention
Subjects in the experimental arm will be administered BM-Allo.MSC
Group II: PlaceboPlacebo Group1 Intervention
Subjects in the control arm will be treated with placebo

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
63 Previous Clinical Trials
5,091 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
2020. "Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04397796.
All > Covid
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top